<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464045</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0097</org_study_id>
    <nct_id>NCT03464045</nct_id>
  </id_info>
  <brief_title>Empa PASS on Urinary Tract Malignancies</brief_title>
  <official_title>Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the risk of urinary tract malignancies in patients&#xD;
      initiating empagliflozin (free or fixed dose combination) compared to patients initiating a&#xD;
      dipeptidyl peptidase-4 (DPP-4) inhibitor and to patients initiating other Sodium glucose&#xD;
      co-transporter-2 (SGLT-2) inhibitors (i.e. two comparator groups)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurence of urinary tract cancer</measure>
    <time_frame>upto 60 months</time_frame>
    <description>first incidence of urinary cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>occurence of bladder cancer</measure>
    <time_frame>upto 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>occurence of renal cancer</measure>
    <time_frame>upto 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurence of other urinary tract cancers</measure>
    <time_frame>upto 60 months</time_frame>
    <description>non-renal, non- urinary bladder, urinary tract cancers</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">98000</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibitors</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT-2 inhibitors</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an observational, comparative, cohort safety study based on European healthcare&#xD;
        databases and includes databases from the UK and Sweden.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes&#xD;
&#xD;
          -  Age over 18 years at index date&#xD;
&#xD;
          -  At least 1 year of membership in the medication database prior to index date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any cancer (excluding non-melanoma skin cancer) recorded at any time&#xD;
             prior to the index date (i.e. during the available look-back time)&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes or other specific non-type 2 diabetes&#xD;
&#xD;
          -  Use of any SGLT-2 inhibitor or any DPP-4 inhibitor (including free and fixed-dose&#xD;
             combinations) recorded at any time prior to index date (i.e. during the available&#xD;
             look-back time).&#xD;
&#xD;
          -  Use of fixed-dose combinations of SGLT-2 inhibitors with DPP-4 inhibitors&#xD;
&#xD;
          -  Diagnosis of end stage renal disease or receipt of renal dialysis recorded at any time&#xD;
             prior to index date (i.e. during the available look-back time)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi Korhonen, 358-50-3652990</last_name>
    <role>Principal Investigator</role>
    <affiliation>pasi.korhonen@epidresearch.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The National Register Data</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Swedish prescribed drug register</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Kingdom Clinical Practice Research Datalink (CPRD)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

